Notice: This company has been marked as potentially delisted and may not be actively trading. Epizyme (EPZM) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period bluebird bio Inc BLUENovember 1, 2023 | morningstar.comCelgene, Jounce Therapeutics in Early Cancer Immunotherapy Development PactMarch 22, 2023 | thestreet.comEpizyme (NASDAQ:EPZM) Earns Hold Rating from Analysts at StockNews.comStockNews.com assumed coverage on shares of Epizyme in a research report on Monday. They issued a "hold" rating on the stock.October 3, 2022 | marketbeat.comAptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal - NasdaqAugust 12, 2022 | nasdaq.comForm SC 14D9/A Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comAugust 12, 2022 | streetinsider.comTrading was temporarily halted for "EPZM" at 07:08 PM with a stated reason of "News pending."August 12, 2022 | marketbeat.comThe past five years for Epizyme (NASDAQ:EPZM) investors has not been profitableAugust 10, 2022 | finance.yahoo.comEpizyme: Q2 Earnings Insights - BenzingaAugust 9, 2022 | benzinga.comEpizyme Reports Second Quarter 2022 Financial Results and Provides Business Update - Business WireAugust 9, 2022 | businesswire.comEpizyme: Q2 Earnings SnapshotAugust 9, 2022 | apnews.comIpsen extends tender offer date in Epizyme deal to get US antitrust clearance - Seeking AlphaAugust 5, 2022 | seekingalpha.comIpsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 - Business WireAugust 5, 2022 | businesswire.comIpsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance - Yahoo FinanceJuly 28, 2022 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION - PR NewswireJuly 26, 2022 | prnewswire.comShareholder Alert - The M&A Class Action Firm Continues Investigating the Merger - FSTX, EPZM, STCN, SIMO - BenzingaJuly 16, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations - PR NewswireJuly 14, 2022 | prnewswire.comEPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM - BenzingaJuly 14, 2022 | benzinga.comForm SC 14D9 Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comJuly 13, 2022 | streetinsider.comEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - GuruFocus.comJuly 11, 2022 | gurufocus.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, RADA, EPZM - GlobeNewswireJuly 10, 2022 | globenewswire.comMoore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm - PR NewswireJuly 6, 2022 | prnewswire.comEpizyme Acquisition By Ipsen: CVR Value (NASDAQ:EPZM) - Seeking AlphaJuly 6, 2022 | seekingalpha.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, USAK, EPZM - PR NewswireJuly 5, 2022 | prnewswire.comEpizyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.comJuly 5, 2022 | marketscreener.comEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - StreetInsider.comJuly 1, 2022 | streetinsider.comEPIZYME ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of EPZM and Encourages Investors to Contact the FirmJuly 1, 2022 | benzinga.comEPIZYME INVESTOR ALERT by the - GuruFocus.comJune 29, 2022 | gurufocus.comIN BRIEF: BioPharma Credit says Epizyme investment to be prepaid | Financial News - London South EastJune 28, 2022 | lse.co.ukShareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM - PR NewswireJune 27, 2022 | prnewswire.comEpizyme, Inc. (NASDAQ:EPZM) Given Average Recommendation of "Hold" by BrokeragesEpizyme, Inc. (NASDAQ:EPZM - Get Rating) has earned a consensus recommendation of "Hold" from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendatioJune 27, 2022 | marketbeat.comShareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZMJune 27, 2022 | prnewswire.comEpizyme (NASDAQ:EPZM) Downgraded by Cowen to "Market Perform"Cowen cut shares of Epizyme from an "outperform" rating to a "market perform" rating in a report on Monday.June 27, 2022 | marketbeat.comWedbush Downgrades Epizyme to Neutral - Benzinga - BenzingaJune 27, 2022 | benzinga.comThinking about buying stock in Epizyme, Acutus Medical, Agile Therapeutics, Axsome Therapeutics, or Evofem Biosciences? - PR NewswireJune 27, 2022 | prnewswire.comEPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders - Business WireJune 27, 2022 | businesswire.comEpizyme Shares Take Flight on Takeover by Ipsen >EPZM - MarketWatchJune 27, 2022 | marketwatch.comEpizyme shares soar 60% on acquisition newsJune 27, 2022 | finance.yahoo.comNorth American Morning Briefing : Hopes for Less Aggressive Fed Spur More Gains for Stocks - Marketscreener.comJune 27, 2022 | marketscreener.comProsus, miners lift European shares to two-week high - NasdaqJune 27, 2022 | nasdaq.comEuropean Shares Set For Steady Opening As Inflation Worries Ease - NasdaqJune 27, 2022 | nasdaq.comFrance's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme - Marketscreener.comJune 27, 2022 | marketscreener.comIpsen to Acquire Epizyme, Expanding Its Portfolio in Oncology - Business WireJune 27, 2022 | businesswire.comHUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China - GuruFocus.comJune 21, 2022 | gurufocus.comEpizyme's Return On Capital Employed Insights - Benzinga - BenzingaJune 9, 2022 | benzinga.comWhy Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?June 9, 2022 | finance.yahoo.comHC Wainwright & Co. Maintains Buy on Epizyme, Lowers Price Target to $6 - Benzinga - BenzingaJune 3, 2022 | benzinga.comEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting - Business WireJune 2, 2022 | businesswire.comEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting - StreetInsider.comJune 2, 2022 | streetinsider.comEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting - Yahoo FinanceJune 2, 2022 | finance.yahoo.comEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual MeetingJune 2, 2022 | finance.yahoo.com Get Epizyme News Delivered to You Automatically Sign up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. EPZM Media Mentions By Week EPZM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPZM News Sentiment▼0.220.47▲Average Medical News Sentiment EPZM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPZM Articles This Week▼00▲EPZM Articles Average Week Get Epizyme News Delivered to You Automatically Sign up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NKTX News COLL News ZYME News BCAX News PAHC News BCYC News AVBP News NUVB News ETNB News LQDA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EPZM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epizyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Epizyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
